RT Journal Article
SR Electronic
T1 An update on the ‘gliptins’
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 138
OP 141
DO 10.1136/dtb.2016.12.0442
VO 54
IS 12
YR 2016
UL http://dtb.bmj.com/content/54/12/138.abstract
AB Progressive impairment of insulin secretion in people with type 2 diabetes leads to blood glucose concentrations worsening over time, often resulting in escalation of blood glucose lowering therapy.1 In 2015/2016, more money was spent on dipeptidyl peptidase-4 (DPP-4) inhibitors (‘gliptins’) than on any other class of antidiabetic drug except for insulins.2 In 2008, we reviewed sitagliptin and vildagliptin.3 Here, we briefly review three other DPP-4 inhibitors, saxagliptin (Onglyza—AstraZeneca), linagliptin (Trajenta—Boehringer Ingelheim) and ▼alogliptin (Vipidia—Takeda), and consider data from recent cardiovascular outcomes studies.